Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Type of gynaecologic surgery:~   * diagnostic laparoscopy~  * sterilization~  * removal of ovarial cyst~  * chromopertubation~  * laparoscopic myomectomy~  * laparoscopic fenestration of ovaria~  * laparoscopic adhesiolysis~2. Age 18-50 years.~3. Evaluated risk of anaesthetic procedure according to ASA (American Society of Anaesthesiologist) classification: ASA I or II.~4. Patients agreed to participate in the study and signed the informed consent.~Exclusion Criteria:~1. ASA III or more~2. Emergency surgery~3. Major laparoscopic surgery i.e. hysterectomy~4. Duration of surgery more than 90 minutes~5. Chronic pain~6. History of hypersensitivity to the active substance or to any of the excipients of study drug (Paracetamol or Etoricoxib)~7. Active peptic ulceration or active gastro-intestinal (GI) bleeding.~8. Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.~9. Pregnancy and lactation~10. Severe hepatic dysfunction (serum albumin \< 25 g/l or Child-Pugh score ≥ 10).~11. Estimated renal creatinine clearance \< 30 mL/min.~12. Children and adolescents under 16 years of age.~13. Inflammatory bowel disease.~14. Congestive heart failure (NYHA II-IV).~15. Patients with hypertension whose blood pressure has not been adequately controlled.~16. Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease, unstable angina.~17. Patient has undergone coronary artery bypass graft surgery, angioplasty, or had myocardial infarction, cerebrovascular accident or transient ischemic attack within the past 6 months.~18. History of drug abuse.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- etoricoxib 120 mg (Type: ACTIVE_COMPARATOR): active control
- 2 (Type: PLACEBO_COMPARATOR): Placebo
- 3 (Type: ACTIVE_COMPARATOR): Paracetamol 1 g and etoricoxib 120 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).